ClinicalTrials.gg
CompletedNCT00614380Updated Feb 13, 2014Results posted

Open Label Study Telmisartan and Amlodipine in Hypertension

A Phase 3 interventional study of telmisartan/amlodipine 40/5 mg fixed combination and telmisartan/amlodipine 80/5 mg fixed combination in Hypertension, sponsored by Boehringer Ingelheim. Completed at 122 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-13.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
976
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
12th of 74
976 · median 381
Started
2008
with 3 others
Phase 3
43 of 122
1 open now
Registered
33rd of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 12th largest by enrollment of the 74 interventional ones that give a count, is one of 4 that started in 2008, is one of 43 in phase 3, and was the 33rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40 mg / amlodipine 5 mg (T40/A5) or telmisartan 80 mg / amlodipine 5 mg (T80/A5) during long-term open-label treatment.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients aged at least 18 years
  2. diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the preceding trial.
  3. failure to respond to six weeks treatment with Amlodipine 5 mg in the run-in period of the preceding trial.

Exclusion criteria

Exclusion Criteria:

  1. pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or are not practising acceptable means of or do not plan to continue using acceptable means of birth control throughout the study
  2. development of any medical condition in the preceding trial that in the investigator's opinion could be worsened by treatment with either Telmisartan 40 mg/Amlodipine 5 mg or Telmisartan 80 mg/Amlodipine 5 mg
  3. discontinuation from the preceding trial because of any adverse event or any other reason
  4. known or suspected secondary hypertension
  5. mean seated Systolic Blood Pressure => 180 mmHg and/or mean seated Diastolic Blood Pressure => 120 mmHg at any visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
976 participants (actual)

Interventions

  • Drugtelmisartan/amlodipine 40/5 mg fixed combination
  • Drugtelmisartan/amlodipine 80/5 mg fixed combination
06

What researchers measure

Primary outcomes

  1. Trough Seated Diastolic Blood Pressure (DBP) Control

    The number of patients who reach the target DBP of \<90mmHg

    Time frame: End of study (34 weeks or last value on treatment)

Secondary outcomes

  1. Trough Seated Systolic Blood Pressure (SBP) Control

    The number of patients who reach the target SBP of \<140mmHg

    Time frame: End of study (34 weeks or last value on treatment)

  2. Change From Baseline in Trough Seated Diastolic Blood Pressure

    Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.

    Time frame: End of study (34 weeks or last value on treatment)

  3. Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7

    The difference between the last available troughs represents the additional reduction in DBP in this study

    Time frame: End of study (34 weeks or last value on treatment)

  4. Change From Baseline in Trough Seated Systolic Blood Pressure

    Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.

    Time frame: End of study (34 weeks or last value on treatment)

  5. Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7

    The difference between the last available troughs represents the additional reduction in SBP in this study

    Time frame: End of study (34 weeks or last value on treatment)

  6. Trough Seated DBP Response

    The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg

    Time frame: End of study (34 weeks or last value on treatment)

  7. Trough Seated SBP Response

    The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg

    Time frame: End of study (34 weeks or last value on treatment)

  8. Trough Blood Pressure (BP) Normality Classes

    The number of patients who reach predefined BP categories

    Time frame: End of study (34 weeks or last value on treatment)

  9. Time to First Additional Antihypertensive

    Time from first intake of medication to first intake of an antihypertensive other than the study drug

    Time frame: At any point during open-label treatment

  10. Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control

    The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment

    Time frame: At any point during open-label treatment

  11. Additional Reduction in DBP by Use of Additional Antihypertensive Therapy

    Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7

    Time frame: At any point during open-label treatment

  12. Additional Reduction in SBP by Use of Additional Antihypertensive Therapy

    Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7

    Time frame: At any point during open-label treatment

  13. Trough DBP Control Pre- and Post- Uptitration

    The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration

    Time frame: At any point during open-label treatment

07

Results

Posted Jan 18, 2010

Participant flow

Participant flow — Overall Study
MilestoneTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Started56420625181
Completed52919824179
Not completed35812
Withdrew: Adverse event14400
Withdrew: Lost to follow-up6100
Withdrew: Non compliant with the protocol12212
Withdrew: Consent withdrawn3100

Outcome measures

PrimaryTrough Seated Diastolic Blood Pressure (DBP) Control

The number of patients who reach the target DBP of \<90mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · Participants
Trough Seated Diastolic Blood Pressure (DBP) Control
ParticipantsTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Yes (DBP<90 mmHg)5041601984
No (DBP>=90 mmHg)4946697
Statistical analysis
  • Telmisartan 40mg and Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg · Cochran-Mantel-Haenszel · Odds ratio (or): 0.34 · 95% CI 0.22 to 0.53
  • Telmisartan 40mg and Amlodipine 5mg vs Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive · Cochran-Mantel-Haenszel · Odds ratio (or): 0.31 · 95% CI 0.12 to 0.81
  • Telmisartan 40mg and Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive · Cochran-Mantel-Haenszel · Odds ratio (or): 0.08 · 95% CI 0.06 to 0.13
  • Telmisartan 80mg and Amlodipine 5mg vs Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive · Cochran-Mantel-Haenszel · Odds ratio (or): 0.91 · 95% CI 0.34 to 2.41
  • Telmisartan 80mg and Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive · Cochran-Mantel-Haenszel · Odds ratio (or): 0.25 · 95% CI 0.16 to 0.39
  • Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive vs Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive · Cochran-Mantel-Haenszel · Odds ratio (or): 0.27 · 95% CI 0.10 to 0.72
SecondaryTrough Seated Systolic Blood Pressure (SBP) Control

The number of patients who reach the target SBP of \<140mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · Participants
Trough Seated Systolic Blood Pressure (SBP) Control
ParticipantsTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Yes (SBP<140 mmHg)4401421689
No (SBP>=140 mmHg)11364992
SecondaryChange From Baseline in Trough Seated Diastolic Blood Pressure

Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough Seated Diastolic Blood Pressure
mmHgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Change From Baseline in Trough Seated Diastolic Blood Pressure-14.18 ± 0.31-12.64 ± 0.52-9.47 ± 1.51-10.17 ± 0.56
SecondaryChange in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7

The difference between the last available troughs represents the additional reduction in DBP in this study

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
mmHgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7-3.54 ± 0.33-5.52 ± 0.55-5.51 ± 1.59-5.74 ± 0.58
SecondaryChange From Baseline in Trough Seated Systolic Blood Pressure

Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough Seated Systolic Blood Pressure
mmHgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Change From Baseline in Trough Seated Systolic Blood Pressure-17.79 ± 0.52-15.91 ± 0.86-12.6 ± 2.5-14.04 ± 0.92
SecondaryChange in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7

The difference between the last available troughs represents the additional reduction in SBP in this study

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
mmHgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7-4.14 ± 0.5-5.62 ± 0.83-3.6 ± 2.41-7.17 ± 0.88
SecondaryTrough Seated DBP Response

The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · Participants
Trough Seated DBP Response
ParticipantsTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Yes (Responder)50417119108
No (Non-responder)4532568
SecondaryTrough Seated SBP Response

The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · Participants
Trough Seated SBP Response
ParticipantsTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Yes (Responder)49017918128
No (Non-responder)5924648
SecondaryTrough Blood Pressure (BP) Normality Classes

The number of patients who reach predefined BP categories

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · Participants
Trough Blood Pressure (BP) Normality Classes
ParticipantsTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive
Optimal (SBP<120 and DBP<80 mmHg)67416
Normal (SBP<130 and DBP<85 mmHg and not optimal)18829312
High-normal (SBP<140 DBP<90 mmHg and not normal)16392934
Stage 1 hypertension (SBP<160 and DBP<100 mmHg1227312105
Stage 2 hypertension (SBP>=160 and DBP>=100 mmHg)138024
SecondaryTime to First Additional Antihypertensive

Time from first intake of medication to first intake of an antihypertensive other than the study drug

Time frame:
At any point during open-label treatment
Reported as:
Mean · Days
Time to First Additional Antihypertensive
DaysTotal
Time to First Additional Antihypertensive85.8 ± 38.4
SecondaryPatients Requiring Additional Antihypertensive Therapy to Achieve DBP Control

The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment

Time frame:
At any point during open-label treatment
Reported as:
Number · Participants
Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control
ParticipantsPre-antihypertensive: Yes (DBP<90 mmHg)Pre-antihypertensive: No (DBP>=90 mmHg)Pre-antihypertensive: Total
Post-antihypertensive: Yes (DBP<90 mmHg)10100110
Post-antihypertensive: No (DBP>=90 mmHg)2106108
Post-antihypertensive: Total12206218
SecondaryAdditional Reduction in DBP by Use of Additional Antihypertensive Therapy

Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7

Time frame:
At any point during open-label treatment
Reported as:
Mean · mmHg
Additional Reduction in DBP by Use of Additional Antihypertensive Therapy
mmHgTotal
Additional Reduction in DBP by Use of Additional Antihypertensive Therapy-5.73 ± 7.65
SecondaryAdditional Reduction in SBP by Use of Additional Antihypertensive Therapy

Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7

Time frame:
At any point during open-label treatment
Reported as:
Mean · mmHg
Additional Reduction in SBP by Use of Additional Antihypertensive Therapy
mmHgTotal
Additional Reduction in SBP by Use of Additional Antihypertensive Therapy-7.53 ± 11.21
SecondaryTrough DBP Control Pre- and Post- Uptitration

The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration

Time frame:
At any point during open-label treatment
Reported as:
Number · Participants
Trough DBP Control Pre- and Post- Uptitration
ParticipantsPre-titration: Yes (DBP<90 mmHg)Pre-titration: No (DBP>=90 mmHg)Pre-titration: Total
Post-titration: Yes (DBP<90 mmHg)17190207
Post-titration: No (DBP>=90 mmHg)0171171
Post-titration: Total17361378

Adverse events

Collected over From day of first dose until one day after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telmisartan 40mg and Amlodipine 5mg—22/976 (2.3%)57/976 (5.8%)
Telmisartan 80mg and Amlodipine 5mg—6/397 (1.5%)45/397 (11.3%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Acute myocardial infarctionCardiac disorders1/9761/397
Cardiac failureCardiac disorders0/9761/397
Mitral valve incompetenceCardiac disorders0/9761/397
Anal abscessInfections and infestations0/9761/397
Post procedural cellulitisInfections and infestations0/9761/397
Thyroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9761/397
DizzinessNervous system disorders1/9761/397
HypotoniaNervous system disorders0/9761/397
Ovarian cystReproductive system and breast disorders0/9761/397
Uterine prolapseReproductive system and breast disorders0/9761/397
Most frequent other events
Most frequent other events
EventTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Back painMusculoskeletal and connective tissue disorders25/97624/397
Oedema peripheralGeneral disorders32/97621/397

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Telmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on AntihypertensiveTotal
Mean54.8 ± 10.952.9 ± 10.654.4 ± 10.852.4 ± 9.653.9 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Telmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTelmisartan 40mg and Amlodipine 5mg + add-on AntihypertensiveTelmisartan 80mg and Amlodipine 5mg + add-on AntihypertensiveTotal
Female24072845365
Male32413417136611
08

Study locations

122 sites
  • 1235.7.32004 Boehringer Ingelheim Investigational Site
    Aywaille, Belgium
  • 1235.7.32010 Boehringer Ingelheim Investigational Site
    Gozée, Belgium
  • 1235.7.32008 Boehringer Ingelheim Investigational Site
    Linkebeek, Belgium
  • 1235.7.32003 Boehringer Ingelheim Investigational Site
    Mol, Belgium
  • 1235.7.32007 Boehringer Ingelheim Investigational Site
    Natoye, Belgium
  • 1235.7.32002 Boehringer Ingelheim Investigational Site
    Tienen, Belgium
  • 1235.7.32005 Boehringer Ingelheim Investigational Site
    Turnhout, Belgium
  • 1235.7.20001 Boehringer Ingelheim Investigational Site
    Coquitlam, British Columbia, Canada
  • 1235.7.20011 Boehringer Ingelheim Investigational Site
    Vancouver, British Columbia, Canada
  • 1235.7.20007 Boehringer Ingelheim Investigational Site
    Bay Roberts, Newfoundland and Labrador, Canada
  • 1235.7.20005 Boehringer Ingelheim Investigational Site
    Mount Pearl, Newfoundland and Labrador, Canada
  • 1235.7.20008 Boehringer Ingelheim Investigational Site
    St. John's, Newfoundland and Labrador, Canada
  • 1235.7.20013 Boehringer Ingelheim Investigational Site
    Corunna, Ontario, Canada
  • 1235.7.20014 Boehringer Ingelheim Investigational Site
    Etobicoke, Ontario, Canada
  • 1235.7.20010 Boehringer Ingelheim Investigational Site
    Hamilton, Ontario, Canada
  • 1235.7.20012 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1235.7.20009 Boehringer Ingelheim Investigational Site
    Ottawa, Ontario, Canada
  • 1235.7.20006 Boehringer Ingelheim Investigational Site
    Sarnia, Ontario, Canada
  • 1235.7.20003 Boehringer Ingelheim Investigational Site
    Sainte-Foy, Quebec, Canada
  • 1235.7.45002 Boehringer Ingelheim Investigational Site
    Birkerød, Denmark
  • 1235.7.45005 Boehringer Ingelheim Investigational Site
    Haderslev, Denmark
  • 1235.7.45008 Boehringer Ingelheim Investigational Site
    Herning, Denmark
  • 1235.7.45009 Boehringer Ingelheim Investigational Site
    Hinnerup, Denmark
  • 1235.7.45001 Boehringer Ingelheim Investigational Site
    Rødovre, Denmark
  • 1235.7.45006 Boehringer Ingelheim Investigational Site
    Rødovre, Denmark
  • 1235.7.45003 Boehringer Ingelheim Investigational Site
    Vaerløse, Denmark
  • 1235.7.45007 Boehringer Ingelheim Investigational Site
    Vildbjerg, Denmark
  • 1235.7.35003 Boehringer Ingelheim Investigational Site
    Joensuu, Finland
  • 1235.7.35004 Boehringer Ingelheim Investigational Site
    Joensuu, Finland
  • 1235.7.35001 Boehringer Ingelheim Investigational Site
    Turku, Finland
  • 1235.7.35002 Boehringer Ingelheim Investigational Site
    Turku, Finland
  • 1235.7.3301H Boehringer Ingelheim Investigational Site
    Aigrefeuille S/Maine, France
  • 1235.7.3306C Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.7.3309B Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.7.3309C Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.7.3309E Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.7.3309D Boehringer Ingelheim Investigational Site
    Avrille, France
  • 1235.7.3309A Boehringer Ingelheim Investigational Site
    Beaucouze, France
  • 1235.7.3305A Boehringer Ingelheim Investigational Site
    Bourg des cptes, France
  • 1235.7.3306D Boehringer Ingelheim Investigational Site
    Briollay, France
  • 1235.7.3308B Boehringer Ingelheim Investigational Site
    Cholet, France
  • 1235.7.3308F Boehringer Ingelheim Investigational Site
    Cholet, France
  • 1235.7.3302C Boehringer Ingelheim Investigational Site
    Garchizy, France
  • 1235.7.3303C Boehringer Ingelheim Investigational Site
    Grandchamps, France
  • 1235.7.3302D Boehringer Ingelheim Investigational Site
    Guerigny, France
  • 1235.7.3310A Boehringer Ingelheim Investigational Site
    Jarny, France
  • 1235.7.3301L Boehringer Ingelheim Investigational Site
    La Chapelle /s Erdre, France
  • 1235.7.3301J Boehringer Ingelheim Investigational Site
    La Chapelle sur Erdre, France
  • 1235.7.3304A Boehringer Ingelheim Investigational Site
    La Fresnais, France
  • 1235.7.3308E Boehringer Ingelheim Investigational Site
    La Jubaudière, France
  • 1235.7.3301G Boehringer Ingelheim Investigational Site
    La Montagne, France
  • 1235.7.3307D Boehringer Ingelheim Investigational Site
    Le Mesnil en Vallée, France
  • 1235.7.3301E Boehringer Ingelheim Investigational Site
    Le Temple de Bretagne, France
  • 1235.7.3309F Boehringer Ingelheim Investigational Site
    Les Ponts de CE, France
  • 1235.7.3305B Boehringer Ingelheim Investigational Site
    Louvigné le Bais, France
  • 1235.7.3307E Boehringer Ingelheim Investigational Site
    Mouliherne, France
  • 1235.7.3306A Boehringer Ingelheim Investigational Site
    Murs Erigne, France
  • 1235.7.3307A Boehringer Ingelheim Investigational Site
    Murs-Erigne, France
  • 1235.7.3301A Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.7.3301B Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.7.3301D Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.7.3301M Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.7.3302A Boehringer Ingelheim Investigational Site
    Nevers, France
  • 1235.7.3302F Boehringer Ingelheim Investigational Site
    Nevers, France
  • 1235.7.3301I Boehringer Ingelheim Investigational Site
    Nort sur Erdre, France
  • 1235.7.3301C Boehringer Ingelheim Investigational Site
    Orvault, France
  • 1235.7.3307F Boehringer Ingelheim Investigational Site
    Parcay les Pins, France
  • 1235.7.3301N Boehringer Ingelheim Investigational Site
    Sautron, France
  • 1235.7.3306B Boehringer Ingelheim Investigational Site
    Segre, France
  • 1235.7.3301F Boehringer Ingelheim Investigational Site
    St Aubin les Châteaux, France
  • 1235.7.3306F Boehringer Ingelheim Investigational Site
    St Georges de Montaigu, France
  • 1235.7.3304B Boehringer Ingelheim Investigational Site
    St Ouen La Rouerie, France
  • 1235.7.3306E Boehringer Ingelheim Investigational Site
    Thouars, France
  • 1235.7.3304C Boehringer Ingelheim Investigational Site
    Tinténiac, France
  • 1235.7.3308A Boehringer Ingelheim Investigational Site
    Vihiers, France
  • 1235.7.82007 Boehringer Ingelheim Investigational Site
    Busan, Korea, Republic of
  • 1235.7.82001 Boehringer Ingelheim Investigational Site
    Daegu, Korea, Republic of
  • 1235.7.82006 Boehringer Ingelheim Investigational Site
    Daejon, Korea, Republic of
  • 1235.7.82004 Boehringer Ingelheim Investigational Site
    Gangwon-Do, Korea, Republic of
  • 1235.7.82008 Boehringer Ingelheim Investigational Site
    Gwangju, Korea, Republic of
  • 1235.7.82002 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.7.82003 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.7.82005 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.7.31008 Boehringer Ingelheim Investigational Site
    Beerzerveld, Netherlands
  • 1235.7.31006 Boehringer Ingelheim Investigational Site
    Bennebroek, Netherlands
  • 1235.7.31004 Boehringer Ingelheim Investigational Site
    Hoogwoud, Netherlands
  • 1235.7.31003 Boehringer Ingelheim Investigational Site
    Musselkanaal, Netherlands
  • 1235.7.31007 Boehringer Ingelheim Investigational Site
    Nijverdal, Netherlands
  • 1235.7.31001 Boehringer Ingelheim Investigational Site
    Oude Pekela, Netherlands
  • 1235.7.31005 Boehringer Ingelheim Investigational Site
    Roelofarendsveen, Netherlands
  • 1235.7.31010 Boehringer Ingelheim Investigational Site
    Voerendaal, Netherlands
  • 1235.7.47002 Boehringer Ingelheim Investigational Site
    Bergen, Norway
  • 1235.7.47003 Boehringer Ingelheim Investigational Site
    Hamar, Norway
  • 1235.7.47004 Boehringer Ingelheim Investigational Site
    Oslo, Norway
  • 1235.7.47001 Boehringer Ingelheim Investigational Site
    Ålesund, Norway
  • 1235.7.63006 Boehringer Ingelheim Investigational Site
    Makati City, Philippines
  • 1235.7.63001 Boehringer Ingelheim Investigational Site
    Manila, Philippines
  • 1235.7.63002 Boehringer Ingelheim Investigational Site
    Manila, Philippines
  • 1235.7.63009 Boehringer Ingelheim Investigational Site
    Manila, Philippines
  • 1235.7.63008 Boehringer Ingelheim Investigational Site
    Pasay City, Philippines

Showing the first 100 of 122 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Neldam S, Edwards C, Lang M, Jones R; TEAMSTA-5 and TEAMSTA-10 Investigators. Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):65-84. doi: 10.1016/j.curtheres.2012.02.004. PubMed 24653513 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008 and a primary completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2008
First posted
Feb 13, 2008
Start
Jan 2008
Primary completionActual
Mar 2009
Results first posted
Jan 18, 2010
Last update
Feb 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00614380
First posted
Feb 13, 2008
Start date
Jan 2008
Primary completion
Mar 2009
Results posted
Jan 18, 2010
Last update
Feb 13, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion